| Literature DB >> 28759115 |
Maryam Sadat Nabavinia1, Aida Gholoobi2, Fahimeh Charbgoo1,3, Mahboobeh Nabavinia4, Mohammad Ramezani1,5, Khalil Abnous3,6.
Abstract
Mucin 1 (MUC1) is a protein usually found on the apical surface of most normal secretory epithelial cells. However, in most adenocarcinomas, MUC1 is overexpressed, so that it not only appears over the entire cell surface, but is also shed as MUC1 fragments into the blood stream. These phenomena pinpoint MUC1 as a potential target for the diagnosis and treatment of cancer; consequently, interest has increased in MUC1 as a molecular target for overcoming cancer therapy challenges. MUC1 currently ranks second among 75 antigen candidates for cancer vaccines, and different antibodies or aptamers against MUC1 protein are proving useful for tracing cancer cells in the emerging field of targeted delivery. The unique properties of MUC1 aptamers as novel targeting agents, and the revolutionary role that MUC1 now plays in cancer therapy, are the focus of this review. Recent advancements in MUC1-targeted cancer therapy are also assessed.Entities:
Keywords: antibody; aptamer; mucin 1 or MUC1; targeted therapy
Mesh:
Substances:
Year: 2017 PMID: 28759115 DOI: 10.1002/med.21462
Source DB: PubMed Journal: Med Res Rev ISSN: 0198-6325 Impact factor: 12.944